Google Suddenly Raises Trade-In Prices In Rare New Offer
The Google Pixel 9 Pro Fold on display at Made By Google at Google on Tuesday, Aug. 13, 2024, in ... More Mountain View, Calif. (AP Photo/Juliana Yamada) Copyright 2024 The Associated Press. All rights reserved
After Samsung unexpectedly raised its trade-in prices, and Apple's iPhone 16 saw its price slashed, Google has joined in with its own major new promotion.
This deal raises trade-in prices when buying the Pixel 9 series to levels I haven't seen from Google before. For those who regularly read my deal stories, you will know that Google typically has some of the lowest valuations (compared to its main rivals) for your used phone. Even for its own Pixel devices, Samsung offers more.
But that appears to have changed with a new Google Store U.K. promotion that tops out at £1,045 trade-in.
The trade-in prices range from a maximum of £675 ($920.50) for the base Pixel 9, £820 ($1118.24) for the Pixel 9 Pro / XL and £1,045 ($1425.07) for the Pixel 9 Pro Fold. Google says this includes a bonus of between £200 ($272.58) and £400 ($545.16) on top of the regular trade-in valuations, with the promotion ending on July 8th. Forbes Samsung Makes New Free Offer To Millions Of Galaxy Phones And Tablets By Janhoi McGregor
Obviously, those top figures are reserved for the latest handsets, which I wouldn't recommend trading in. Your Pixel 8, Galaxy S24 or iPhone 15 will continue to be excellent phones for several more years (and in some cases, better than their successors). But there are some solid deals here. Check out the pricing below when buying the Pixel 9 Pro. Google Pixel 7 Pro - £454 ($618.75)
Google Pixel 6 Pro - £415 ($565.60)
Google Pixel 5 - £377 ($513.81)
Apple iPhone 14 Pro Max - £657 ($895.42)
Apple iPhone 11 Pro Max - £447 ($609.21)
Samsung Galaxy S23 Ultra - £517 ($704.62)
Samsung Galaxy S10 Plus - £373 ($508.36)
Let's address the obvious takeaway from these prices: no one will ever give you more money than that for your defunct Google Pixel 5. It is out of the software support window and the last Google device released before the modern rebrand. It's museum fodder. So receiving nearly £400 ($545.16) for the 2020 handset is a deal that shouldn't be sniffed at. Google Comfortably Beats The Competition With New Pixel 9 Trade In Deal
These new Google valuations outstrip the pricing on the secondary market and rival manufacturer trade-in prices. For example, Samsung will pay £449 ($611.94) for the Galaxy S23 Ultra and it doesn't even accept the Galaxy S10 Plus for trade-in.
Google also clears Apple's iPhone 14 Pro Max price by almost £200 (£470 / $640.56 versus £657). The gap is even bigger with the iPhone 11 Pro Max, which Apple will pay £165 for ($224.88) compared to Google's £447.
I have covered almost every Google deal in the last two years and I haven't seen the company raise its trade-in prices by this much before. Perhaps it heard the grumbles about how poorly it has historically valued your old phone, or it saw Samsung's similarly high price trade-in deal. Whatever the reason, this is good news for customers. Forbes Google Battery Warning Made Worse By Pixel Trade-In Problems By Janhoi McGregor
I looked through the terms and conditions and they appear to be reasonable and normal. The only thing that gives me pause is that the company handling Google's trade-in scheme for this deal, PCS Wireless, will obviously inspect the device and only send it back if results show it is worth less than 75% of the estimated value. If the investigation shows the device is worth 75%, or more (but less than the original quote), then you will have to accept that figure, with no argument.
The inspection criteria, again, seems reasonable; making sure the phone powers on, data is wiped, ensuring the phone isn't counterfeit and more fairly standard expectations. There may be more to it and perhaps PCS will nitpick. I'd be interested to hear from those who have successfully, or unsuccessfully, received the full whack from Google for their old phone. Let me know.
If you're a particularly enterprising deal hunter, it is worth buying a cheap second-hand Pixel phone (these have the best price-to-trade-in ratio) and sending it to Google to save some money. Or, raid your drawer for a (working) used phone and see what Google will pay for it because the list of eligible phones is surprisingly long.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
23 minutes ago
- CNET
Reserve Samsung's New Galaxy Z Flip 7 and Fold 7 and Get a $50 Credit
Samsung's latest Galaxy Z foldable phones are soon to be unveiled at the company's upcoming Unpacked event, which takes place July 9. But you don't have to wait to lock in your next device; you can reserve one now at and earn a $50 Samsung credit. It's not yet clear just how many new phones we'll be getting -- will there be more than the usual two? -- but Samsung has been teasing Ultra-grade and slim foldable phones for this launch. Samsung Newsroom posts have pointed to a more "powerful camera" and "AI-powered tools," and have also noted that its "newest Galaxy Z series is the thinnest, lightest and most advanced foldable yet." So, it's possible Samsung could unveil the Galaxy Z Flip 7, Z Fold 7 and then the Z Fold Ultra, or whatever it ends up calling these devices. But wait, there's more! There are also rumors surrounding a more affordable Galaxy Z Flip 7 FE phone. Leaks show renders of the rumored device, which appears similar to the Galaxy Z Flip 6, but it's possible the phone could swap out the Snapdragon chip for an Exynos processor to keep that price down. Ultimately, we'll have to wait and see what Samsung has up its sleeve. But if you're eager to get your hands on one of the latest devices, you can head to Samsung's site to reserve your future phone and score that $50 Samsung credit. You can also enter a sweepstakes for the chance to win an additional $5,000 credit. These offers are only available on and the Shop Samsung app. If you'd like to explore Samsung's other phone options, check out list of the best Samsung phones to buy right now.
Tom's Guide
27 minutes ago
- Tom's Guide
Get a free iPad and Apple Watch with your iPhone 16 purchase at Verizon — here's how to get yours
With 4th of July sales around the corner, now is an excellent time to save big. For example, here's one deal that gets you two of my favorite Apple devices for free. For a limited time, Verizon is offering a free iPad (A16) or Apple Watch 10 with your iPhone 16 Pro. Additionally, new customers can get the iPhone 16 Pro for free with a 36-month plan and eligible unlimited data plan. That's one of the best Verizon phone deals I've seen. For more ways to save, check out our Verizon promo codes page. iPhone 16 Pro: free w/ new line + unlimited @ VerizonWhen it comes to power, the iPhone 16 Pro will leave most phones in the dust. Right now at Verizon you can get the iPhone 16 Pro for free with a new line and Unlimited Ultimate Plan. Additionally, you'll get a free Apple Watch and iPad with your purchase. (Note: Both items will require their respective data plans). The iPhone 16 Pro packs a 6.3-inch 2622 x 1206 OLED display with 120Hz refresh, A18 Pro CPU, and 128GB of storage. Rear cameras include a 48MP main (f/1.78), 48MP ultrawide (f/2.2), and 12MP telephoto (5x, f/2.8). There's also a 12MP (f/1.9) front camera. In our iPhone 16 Pro review, we said the Pro is the best value as it packs the same 5x telephoto zoom as the larger Pro Max, but in a smaller design and for $200 less. The iPhone 16 Pro is quite possibly one of the best phones on the market. Apple increased the size of the iPhone 16 Pro's display to 6.3 inches, boosted the battery life and upgraded the telephoto camera to 5x zoom, helping close the gap between the Pro and the Pro Max version. Yes, you could argue that the iPhone 17 Pro is right around the corner, but the iPhone 16 Pro still has plenty of years left in its life. It's equipped with all of the latest Apple Intelligence features, and a new Camera Control to make adjusting and taking snapshots easier. It's one of the best iPhones around, and the best camera phone we've tested to date. Pair it with an Apple Watch 10 and a new iPad and you've got one of the best deals of the summer.
Yahoo
32 minutes ago
- Yahoo
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2). 'We are highly encouraged by the FDA's positive feedback on our proposed development plan for this important program. We believe CUE-401, with its first-in-class mechanism exploiting the combined activities of TGF-β and IL-2 is a potentially disruptive approach differentiated from other Treg-directed therapies, and has the potential to provide durable, long-lasting immune rebalance and tolerance addressing multiple, significant disease indications,' said Daniel Passeri, chief executive officer of Cue Biopharma. Dr. Dan Baker, chief development officer of Cue Biopharma commented, 'CUE-401's mechanistic design extends beyond nTreg proliferation by transforming effector/autoreactive responses to an anti-inflammatory and/or suppressive response, with the prospects of establishing tolerance. The combination of interleukin 2 (IL-2) and transforming growth factor beta (TGF-ß) is considered the 'master switch' for conversion of activated T effector cells into T cells with a regulatory phenotype.' About CUE-401CUE-401 is a preclinical, bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) through the co-activity of modified variants of transforming growth factor beta (TGF-β) and interleukin 2 (IL-2) with therapeutic potential across a range of T-cell mediated autoimmune and inflammatory diseases. CUE-401 has been engineered to harness the Treg induction capacity of TGF-β combined with IL-2 signaling to provide what Cue Biopharma believes to be superior quality and stability of Tregs. The design and specifications of CUE-401 have been guided by leading scientific publications demonstrating that both IL-2 and TGF-β are required for stable and efficient production of active and durable Tregs. CUE-401 is designed to overcome multiple hurdles required to exploit the therapeutic potential of a master switch with a first-in-class, bispecific molecule integrating a masked TGF-ß, with our clinically validated, attenuated IL-2 with an antibody Fc fragment. This novel design provides for 'conditional binding' and avoids off target activity, simplifies manufacturing and has highly differentiated findings in multiple pre-clinical models. In these models, CUE-401 behaves as a master switch to convert autoreactive effector T cells (inflammatory cells) into stable, induced T-regulatory cells (iTregs). These findings suggest that CUE-401 acts by establishing a 'tolerance positive feedback loop' that not only increases nonspecific Treg populations, but critically, reduces and converts specific autoreactive T cells into transdifferentiated iTregs that are specific for the disease-causing autoantigens. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit and follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's expectations regarding the planned IND filing for CUE-401; the Company' expectations regarding the potential characteristics and benefit of CUE-401; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'would,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'project,' 'estimate,' 'anticipate,' 'strategy,' 'future,' 'likely' or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's pipeline of product candidates and platforms, and its strategies, prospects, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to successfully advance is development plan for CUE-401; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ('FDA') or other governmental approvals for its product candidates, including FDA clearance of any future IND submission for CUE-401, and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the near term; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Media ContactJonathan PappasLifeSci Communicationsjpappas@
